<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BETOPTIC S - betaxolol hydrochlorideÂ suspensionÂ </strong><br>Alcon Laboratories, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use BETOPTIC SÂ® safely and effectively. See full prescribing information for BETOPTIC SÂ®.<br><br>BETOPTIC SÂ® (betaxolol hydrochloride ophthalmic suspension) 0.25% as base, Sterile topical ophthalmic drops<br><br>Initial U.S. Approval: 1985</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Use in Specific Populations, Pediatric Use (<a href="#ID_d0698803-0196-9572-a983-05b4c6b57c9d">8.4</a>)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  6/2007 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">BETOPTIC SÂ® is a beta-adrenergic receptor inhibitor indicated for the treatment of elevated intraocular pressure in patients with chronic open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> (<a href="#ID_B1C0CB67-2210-6F82-463E-1688DAED80D0">1</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul><li>Instill one drop in the affected eye(s) twice daily (<a href="#ID_935BA179-8DAD-3502-EEC1-FAF593AB1279">2</a>) </li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Bottles filled with 2.5, 5, 10, and 15 mL of 0.25% sterile ophthalmic suspension (<a href="#ID_1E92A6F0-2DFE-E120-A709-0A39FBFB207A">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product (<a href="#ID_2AF11CA5-4322-0319-3D06-95E3171192D8">4</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span>, second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, and <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span> (<a href="#ID_2AF11CA5-4322-0319-3D06-95E3171192D8">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Same adverse reactions found with systemic administration of beta-adrenergic receptor inhibitors may occur with topical ophthalmic administration (<a href="#ID_61627fc3-93ac-a1e6-9d3f-7a942e9c3100">5.1</a>). </li>
<li>Beta-adrenergic receptor inhibitors may mask the signs and symptoms of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and should be administered with caution in diabetic patients subject to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (<a href="#ID_4310dca8-9ef3-2d6e-decd-096902356123">5.3</a>).</li>
<li>Beta-adrenergic receptor inhibitors may mask certain clinical signs (e.g. <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) or <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> (<a href="#ID_2ef81a95-681f-16d1-382d-75ddccf4f41c">5.4</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most frequent adverse reaction is transient <span class="product-label-link" type="condition" conceptid="372912" conceptname="Visual discomfort">ocular discomfort</span> (<a href="#ID_4b9b2127-fa37-03e2-10ed-a05060d7168e">6.1</a>).<br><br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc. at 1-800-757-9195 or FDA at 1-800-FDA-1088 or </span><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a><span class="Bold">.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 General</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Surgical Anesthesia</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> and Obstructive Pulmonary Disease</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">Atopy</span>/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Cerebrovascular Insufficiency</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="437860" conceptname="Choroidal detachment">Choroidal Detachment</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Additional Potential Adverse Reactions Associated with Betaxolol</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Oral Beta-Adrenergic Receptor Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Catecholamine-Depleting Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Concomitant Adrenergic Psychotropic Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_B1C0CB67-2210-6F82-463E-1688DAED80D0"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">BETOPTIC SÂ® Ophthalmic Suspension 0.25% is indicated for the treatment of elevated intraocular pressure in patients with chronic open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_935BA179-8DAD-3502-EEC1-FAF593AB1279"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Instill one drop of BETOPTIC SÂ® Ophthalmic Suspension 0.25% in the affected eye(s) twice daily. It may be used alone or in combination with other intraocular pressure lowering medications.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_1E92A6F0-2DFE-E120-A709-0A39FBFB207A"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Bottle filled with 2.5, 5, 10, and 15Â mL of 0.25% sterile ophthalmic suspension</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_2AF11CA5-4322-0319-3D06-95E3171192D8"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">BETOPTIC SÂ® Suspension is contraindicated in patients with:<br>â€¢ <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span><br>â€¢ greater than a <span class="product-label-link" type="condition" conceptid="314379" conceptname="First degree atrioventricular block">first degree atrioventricular block</span><br>â€¢ <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span><br>â€¢ patients with overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span><br>â€¢ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this product.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_9F7D2586-00E3-E2AB-55BB-50C322D19F5C"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_61627fc3-93ac-a1e6-9d3f-7a942e9c3100"></a><a name="section-5.1"></a><p></p>
<h2>5.1 General</h2>
<p class="First">As with many topically applied ophthalmic drugs, this drug is absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic receptor inhibitors may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, have been reported with topical application of beta-adrenergic receptor inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1a59d2f4-6448-95f4-7cbb-37d6d8594fcc"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">BETOPTIC SÂ® Suspension has been shown to have a minor effect on heart rate and blood pressure in clinical studies. Caution should be used in treating patients with a history of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> or <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>. Treatment with BETOPTIC SÂ® should be discontinued at the first signs of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4310dca8-9ef3-2d6e-decd-096902356123"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</h2>
<p class="First">Beta-adrenergic receptor inhibitors should be administered with caution in patients subject to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or to diabetic patients (especially those with labile <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are receiving insulin or oral hypoglycemic agents.Â <br><br>Beta-adrenergic receptor inhibitors may mask the signs and symptoms of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2ef81a95-681f-16d1-382d-75ddccf4f41c"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></h2>
<p class="First">Beta-adrenergic receptor inhibitors may mask certain clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> should be managed carefully to avoid abrupt withdrawal of beta-adrenergic receptor inhibitors, which might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_85fc9076-d54d-930b-cf05-59a12aaaaa3e"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span></h2>
<p class="First">Beta-adrenergic receptor inhibitors have been reported to potentiate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> consistent with certain myasthenic symptoms (e.g., <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span> and generalized <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4fd4e939-cda7-a6de-ae99-92785453514b"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Surgical Anesthesia</h2>
<p class="First">The necessity or desirability of withdrawal of beta-adrenergic receptor inhibitors prior to major surgery is controversial. Beta-adrenergic receptor inhibitors impair the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor inhibitors have experienced protracted, severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. In patients undergoing elective surgery, consider gradual withdrawal of beta-adrenergic receptor inhibitors. If necessary during surgery, the effects of beta-adrenergic receptor inhibitors may be reversed by sufficient doses of adrenergic agonists.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_10ba2aee-8ca3-03b5-ff6b-22fc8ec6bbdb"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> and Obstructive Pulmonary Disease</h2>
<p class="First">Caution should be exercised in the treatment of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> patients with excessive restriction of pulmonary function. There have been reports of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic attacks</span> and pulmonary distress during betaxolol treatment. Although re-challenges of some such patients with ophthalmic betaxolol has not adversely affected pulmonary function test results, the possibility of adverse pulmonary effects in patients sensitive to beta-adrenergic receptor inhibitors cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_01f13d33-3336-c923-a242-67068ad0aff5"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">Atopy</span>/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></h2>
<p class="First">While taking beta-adrenergic receptor inhibitors, patients with a history of <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopy</span> or a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ead2b8ba-2bae-512c-167f-0ba8bf02333e"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">In patients with angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, the immediate treatment objective is to reopen the angle. This may require constricting the pupil. Betaxolol has little or no effect on the pupil and should not be used alone in the treatment of angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f82de070-3652-70bc-e860-e7bab12b271c"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Cerebrovascular Insufficiency</h2>
<p class="First">Because of potential effects of beta-adrenergic receptor inhibitors on blood pressure and pulse, these inhibitors should be used with caution in patients with cerebrovascular insufficiency. If signs or symptoms suggesting reduced cerebral blood flow develop following initiation of therapy with BETOPTIC SÂ®, alternative therapy should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_18d6f85d-1088-2569-d734-18097bdad378"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span></h2>
<p class="First">Bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> may occur with use of multiple dose containers of topical ophthalmic products when these containers are inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. Instruct patients on appropriate instillation techniques. [see <span class="Italics"><a href="#_splSectionPLRPatientInfo">Patient Counseling Information (17)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fa2b7a01-7766-963f-02de-dacf19204921"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="437860" conceptname="Choroidal detachment">Choroidal Detachment</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437860" conceptname="Choroidal detachment">Choroidal detachment</span> after filtration procedures has been reported with the administration of aqueous suppressant therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_29D808D1-BEA5-78AC-A969-CEB19844699E"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4b9b2127-fa37-03e2-10ed-a05060d7168e"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>In clinical trials, the most frequent adverse reaction associated with the use of BETOPTIC SÂ® Ophthalmic Suspension 0.25% has been transient <span class="product-label-link" type="condition" conceptid="372912" conceptname="Visual discomfort">ocular discomfort</span>. The following other adverse reactions have been reported in small numbers of patients:</p>
<p>Ocular: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, corneal punctuate <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, foreign body sensation, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, tearing, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dryness of eyes</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, discharge, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span>, decreased visual acuity and crusty lashes.</p>
<p>Systemic adverse reactions include:</p>
<p>Cardiovascular: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> and congestive failure.</p>
<p>Pulmonary: Pulmonary distress characterized by <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, thickened bronchial secretions, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>.</p>
<p>Central Nervous System: <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, and increase in signs and symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.</p>
<p>Other: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Hives</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> and <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>. Perversions of taste and smell have been reported.</p>
<p>In a 3-month, double-masked, active-controlled, multicenter study in pediatric patients, the adverse reaction profile of BETOPTIC SÂ® Ophthalmic Suspension 0.25% was comparable to that seen in adult patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_094437bc-64eb-866f-e95c-297b0103dae5"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Additional Potential Adverse Reactions Associated with Betaxolol</h2>
<p class="First">Additional medical events reported with other formulations of betaxolol include <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, decreased corneal sensitivity, corneal punctuate staining which may appear in dendritic formations, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="434374" conceptname="Anisocoria">anisocoria</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_DFD4E4B6-FF9A-C982-497D-4F65FB515A55"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9b453bee-e1ae-d9d3-8779-09b1b403c598"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Oral Beta-Adrenergic Receptor Inhibitors</h2>
<p class="First">Patients who are receiving a beta-adrenergic receptor inhibitor orally and BETOPTICÂ SÂ® Ophthalmic Suspension 0.25% should be observed for a potential additive effect either on the intraocular pressure or on the known systemic effects of beta blockade.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4edfb275-cad0-d20e-4897-039e28c93d97"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Catecholamine-Depleting Drugs</h2>
<p class="First">Close observation of the patient is recommended when a betaâ€“adrenergic receptor inhibitor is administered to patients receiving<span class="Bold"></span>catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> which may result in <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_379def00-14e1-10c4-5666-a6e76be9bdbb"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Concomitant Adrenergic Psychotropic Drugs</h2>
<p class="First">Betaxolol is an adrenergic receptor inhibitor; therefore, caution should be exercised in patients using concomitant adrenergic psychotropic drugs.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_C6D7BF73-9502-F538-8288-05A2641DD5F0"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_11ff3c38-0cb1-bbb1-15f4-074206d5463c"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Teratogenic effects<br></span><span class="Italics">Pregnancy Category C: </span>Reproduction, teratology, and peri- and postnatal studies have been conducted with orally administered betaxolol HCl in rats and rabbits. There was evidence of drug related postimplantation loss in rabbits and rats at dose levels above 12Â mg/kg and 128Â mg/kg, respectively. Betaxolol HCl was not shown to be teratogenic, however, and there were no other adverse effects on reproduction at subtoxic dose levels. There are no adequate and well-controlled studies in pregnant women.</p>
<p>BETOPTIC SÂ® Ophthalmic Suspension 0.25% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_bba3e34f-d721-326f-5ccd-ae939a461315"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether betaxolol HCl is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when BETOPTICÂ SÂ® Ophthalmic Suspension 0.25% is administered to nursing women.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_d0698803-0196-9572-a983-05b4c6b57c9d"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and IOP-lowering effect of BETOPTIC SÂ® Ophthalmic Suspension 0.25% has been demonstrated in pediatric patients in a 3-month, multicenter, double-masked, active-controlled trial.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_38a15d84-3d5d-a6e2-9d96-823ed58b5672"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_F4340750-900A-1EAA-666E-87DB6A2BC403"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No information is available on overdosage in humans. The oral LD<span class="Sub">50</span> of the drug ranged from 350-920Â mg/kg in mice and 860-1050Â mg/kg in rats. The symptoms which might be expected with an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of a systemically administered beta-1-adrenergic receptor inhibitor are <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and acute <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.</p>
<p>A topical <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of BETOPTIC SÂ® Ophthalmic Suspension 0.25% may be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> from the eye(s) with warm tap water.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_D1B2CF44-6730-B599-44E3-5BD3D0F9C2E9"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">BETOPTIC SÂ® Ophthalmic Suspension 0.25% contains betaxolol hydrochloride, a cardioselective beta-adrenergic receptor inhibitor, in a sterile resin suspension formulation. Betaxolol hydrochloride is a white, crystalline powder, with a molecular weight of 343.89. The chemical structure is presented below.<br><img alt="Chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=71659a34-efad-4147-81c7-da10985e9224&amp;name=Chemical.jpg"><br></p>
<p>Empirical Formula:<br>C<span class="Sub">18</span>H<span class="Sub">29</span>NO<span class="Sub">3</span>â€¢HCl<br>Chemical Name:<br>(Â±)-1-[p-[2-(cyclopropylmethoxy) ethyl]phenoxy]-3-(isopropylamino)-2-propanol hydrochloride.</p>
<p>Each mL of BETOPTIC SÂ® Ophthalmic Suspension 0.25% contains: <span class="Bold">Active: </span>betaxolol HCl 2.8Â mg equivalent to 2.5Â mg of betaxolol base. <span class="Bold">Preservative: </span>benzalkonium chloride 0.01%. <span class="Bold">Inactives: </span>mannitol, poly(styrene-divinyl benzene) sulfonic acid, carbomerÂ 934P, edetate disodium, hydrochloric acid or sodium hydroxide (to adjust pH) and purified water.</p>
<p>BETOPTIC SÂ® Ophthalmic Suspension 0.25% has pH of approximately 7.6 and an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of approximately 290Â mOsmol/kg.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_F2F5B56F-830D-F533-4F06-9E37B9BA9401"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_c2cdc3c3-ebc1-3100-f9e1-7d7c30538201"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Betaxolol HCl, a cardioselective (beta-1-adrenergic) receptor inhibitor, does not have significant membrane-stabilizing (local anesthetic) activity and is devoid of intrinsic sympathomimetic action. Orally administered beta-adrenergic receptor inhibitors reduce <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> in healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor antagonists may inhibit the sympathetic stimulatory effect necessary to maintain adequate cardiac function.</p>
<p>When instilled in the eye, BETOPTIC SÂ® Ophthalmic Suspension 0.25% has the action of reducing elevated intraocular pressure, whether or not accompanied by <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Ophthalmic betaxolol has minimal effect on pulmonary and cardiovascular parameters.</p>
<p>Elevated IOP presents a major risk factor in glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> and visual field loss. Betaxolol has the action of reducing elevated as well as normal intraocular pressure and the mechanism of ocular hypotensive action appears to be a reduction of aqueous production as demonstrated by tonography and aqueous fluorophotometry.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_980cfb18-3350-250d-feee-c007b816f4df"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The onset of action with betaxolol can generally be noted within 30 minutes and the maximum effect can usually be detected 2 hours after topical administration. A single dose provides a 12-hour reduction in intraocular pressure. In some patients, the intraocular pressure lowering responses to BETOPTICÂ SÂ® may require a few weeks to stabilize. As with any new medication, careful monitoring of patients is advised.</p>
<p>Ophthalmic betaxolol solution at 1% (one drop in each eye) was compared to placebo in a crossover study challenging nine patients with reactive airway disease. BetaxololÂ HCl had no significant effect on pulmonary function as measured by Forced Expiratory Volume in 1 second (FEV<span class="Sub">1</span>), Forced <span class="product-label-link" type="condition" conceptid="4147814" conceptname="Vital capacity">Vital Capacity</span> (FVC), FEV<span class="Sub">1</span>/FVC and was not significantly different from placebo. The action of isoproterenol, a beta stimulant, administered at the end of the study was not inhibited by ophthalmic betaxolol.</p>
<p>No evidence of cardiovascular beta adrenergic-blockade during exercise was observed with betaxolol in a double-masked, crossover study in 24 normal subjects comparing ophthalmic betaxolol and placebo for effects on blood pressure and heart rate.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_ADB86EF0-6131-9E06-AC5B-5F689E46D651"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_41235ab4-7852-ef03-e54b-9a89d70182c3"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Lifetime studies with betaxolol HCl have been completed in mice at oral doses of 6, 20 or 60Â mg/kg/day and in rats at 3, 12 or 48Â mg/kg/day; betaxolol HCl demonstrated no carcinogenic effect. Higher dose levels were not tested.</p>
<p>In a variety of <span class="Italics">inÂ vitro </span>and <span class="Italics">inÂ vivo </span>bacterial and mammalian cell assays, betaxololÂ HCl was nonmutagenic.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_33105BD0-7E7B-EFF7-2C6D-E1B8175C9078"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In controlled, double-masked studies, the magnitude and duration of the ocular hypotensive effect of BETOPTIC SÂ® Ophthalmic Suspension 0.25% and BETOPTICÂ® Ophthalmic Solution 0.5% were clinically equivalent. BETOPTICÂ SÂ® Suspension was significantly more comfortable than BETOPTICÂ® Solution.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_1ED83F5E-DB90-AC68-6D46-F8E4261936A0"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">BETOPTIC SÂ® Ophthalmic Suspension 0.25% is supplied as follows: 2.5, 5, 10 and 15Â mL in plastic ophthalmic DROP-TAINERÂ® dispensers. Tamper evidence is provided with a shrink band around the closure and neck area of the DROP-TAINERÂ® package.</p>
<p>5 mL: <span class="Bold">NDC</span>0065-0246-05<br>10 mL: <span class="Bold">NDC</span>0065-0246-10<br>15 mL: <span class="Bold">NDC</span>0065-0246-15</p>
<p><span class="Bold">Storage and Handling<br></span>Store upright at 2Â° - 25Â°C (36Â° - 77Â°F).<br>Shake well before using.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_981DBD21-924E-9C56-E5C1-950DDC32A6E2"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">How to Use The DROP-TAINERÂ® Bottle</p>
<p>The DROP-TAINERÂ® bottle is designed to assure the delivery of a precise dose of medication. Before using your DROP-TAINERÂ® bottle, read the complete instructions carefully.<br><img alt="handling the bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=71659a34-efad-4147-81c7-da10985e9224&amp;name=Picture1.jpg"></p>
<p>1. If you use other topically applied ophthalmic medications, they should be administered at least 10Â minutes before BETOPTICÂ SÂ®.<br>2. Wash hands before each use.<br>3. Before using the medication for the first time, be sure the Safety Seal on the bottle isunbroken.<br>4. Tear off the Safety Seal to break the seal.<br>5. Before each use, shake well and remove the screw cap.<br>6. Invert the bottle and hold the bottle between your thumb and middle finger, with the tips of the fingers pointing towards you.<br><img alt="administering the medication" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=71659a34-efad-4147-81c7-da10985e9224&amp;name=picture2.jpg"></p>
<p>7. Tilt your head back and position the bottle above the affected eye. DO NOT TOUCH THE EYE WITH THE TIP OF THE DROPPER.<br>8. With the opposite hand, place a finger under the eye. Gently pull down until a â€œVâ€? pocket is made between your eye and lower lid.<br>9. With the hand holding the bottle, place your index finger on the bottom of the bottle. Push the bottom of the bottle to dispense one drop of medication. DO NOT SQUEEZE THE SIDES OF THE BOTTLE.<br>10. Repeat 6, 7, 8 and 9 with other eye if instructed to do so.<br>11. Replace screw cap by turning until firmly touching the bottle. </p>
<p>Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye(s) or surrounding structures. Patients should also be instructed that ocular solutions, if handled improperly, could become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious damage to the eye(s) and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated solutions.</p>
<p>Patients should be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>), they should immediately seek their physicianâ€™s advice concerning the continued use of the present multidose container.</p>
<p>Patients requiring concomitant topical ophthalmic medications should be instructed to administer these at least 10 minutes before instilling BETOPTICÂ SÂ® Suspension.</p>
<p>Â© 2003, 2007, 2008, 2009 Alcon, Inc.<br>Alcon Laboratories, Inc.<br>Fort Worth, Texas76134<br><span class="Bold">9002808-0109</span></p>
</div>
<div class="Section" data-sectionCode="48780-1">
<a name="ID_987C0651-DFFE-91B1-D37D-094027FF1F86"></a><a name="section-16"></a><p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_2CC3FBEF-92D6-69AE-9329-C8E499E1AC2E"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 0065-0246-05<br><br>AlconÂ®<br>Betoptic SÂ®<br>(betaxolol HCl ophthalmic suspension)<br>0.25% as base<br><br>5 mL Sterile<br><img alt="Betoptic S 5 mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=71659a34-efad-4147-81c7-da10985e9224&amp;name=Carton.jpg"></p>
<p><img alt="Betoptic S 5 mL label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=71659a34-efad-4147-81c7-da10985e9224&amp;name=Label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BETOPTIC S Â 		
					</strong><br><span class="contentTableReg">betaxolol hydrochloride suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0065-0246</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Betaxolol Hydrochloride</strong> (Betaxolol) </td>
<td class="formItem">Betaxolol Hydrochloride</td>
<td class="formItem">2.8Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Mannitol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Edetate Disodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hydrochloric Acid</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Benzalkonium Chloride</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0065-0246-10</td>
<td class="formItem">10 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0065-0246-05</td>
<td class="formItem">5 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0065-0246-15</td>
<td class="formItem">15 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019845</td>
<td class="formItem">01/15/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Alcon Laboratories, Inc.
							(008018525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Alcon Laboratories, Inc. (008018525)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Alcon Laboratories, Inc.</td>
<td class="formItem"></td>
<td class="formItem">008018525</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2008<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a2957c48-05ee-4300-b55a-11461b4a9548</div>
<div>Set id: 71659a34-efad-4147-81c7-da10985e9224</div>
<div>Version: 3</div>
<div>Effective Time: 20080519</div>
</div>
</div>Â <div class="DistributorName">Alcon Laboratories, Inc.</div></p>
</body></html>
